The global Genital Warts Treatment Market To Surpass US$ 2,253.6 Million By 2028


Posted February 8, 2022 by SANJAYCMI

Increasing prevalence of sexually transmitted diseases (STDs) and Human Papilloma Virus (HPV) infection cases are expected to increase the growth of the global genital warts treatment market over the forecast period.
 
The global genital warts treatment market is gaining significant traction with growing cases of sexually transmitted disease (STD) and human papillomavirus (HPV)

Market Overview

There are various methods of treating genital warts. Medications are applied to the infected area, and blisters form under warts to stop blood flow. The topical medication may be applied by a healthcare provider or can be self-applied. Surgery may also be recommended for warts that are large or resistant to other treatments. Certain types of HPV can lead to cancer in the vagina and cervix if left untreated. Surgical removal requires an anesthetic and may also involve a procedure involving intense light or an electric current.

Market Dynamics

Increasing prevalence of sexually transmitted disease (STD) and human papillomavirus (HPV) infection is expected to drive growth of the global genital warts treatment market during the forecast period. According to the World Health Organization (WHO), in November 2021, around 374 million new infections with 1 of the 4 sexually transmitted infections (STIs) are reported including syphilis, gonorrhea, chlamydia, and trichomoniasis. According to the Centers for Disease Control and Prevention (CDC), in 2018, over 43 million HPV infections were reported across the U.S. Such massive prevalence of STDs and HPVs has necessitated the treatment adoption.

Request a Sample Copy: https://www.coherentmarketinsights.com/insight/request-sample/4534

However, low diagnostic rates due to lack of awareness is expected to hamper the global genital warts treatment market growth over the forecast period.

Impact of COVID-19

The global genital warts treatment market witnessed significant decline in growth due to the outbreak of the global genital warts treatment market. Since the outbreak of the novel coronavirus in December 2019, many countries suspended international travel and implemented strict restrictions on international trades. Nationwide lockdown policies were adopted, rendering manufacturing activities to brief interruption. However, the rollout of COVID-19 vaccines and declining cases are expected to aid the market to regain its lost traction in the near future.

Browse Research Report: https://www.coherentmarketinsights.com/market-insight/genital-warts-treatment-market-4534

Key Takeaways

• The global genital warts treatment market is expected to witness significant growth, registering a CAGR of 4.7% over the forecast period. This is owing to ongoing research activities to develop novel treatment options. For instance, in January 2021, Verrica Pharmaceuticals announced positive results of its Phase III CAMP trials of VP-102, a proprietary drug for molluscum & genital warts treatment.

• Among regions, North America is expected to witness significant growth in the global genital warts treatment market during the forecast period. This is owing to the presence of robust healthcare infrastructure and the availability of advanced diagnostic procedures across the region.

• Key players operating in the global genital warts treatment market are Sanofi S.A., AbbVie Inc., Perrigo Company PLC, 3M, Lee's Pharmaceutical Holdings Ltd, Cassiopea, Glenmark Pharmaceuticals, Bausch Health, and Novartis International AG.

Buy-Now this Research Report: https://www.coherentmarketinsights.com/insight/buy-now/4534
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Coherent Market Insights
Phone +1-206-701-6702
Business Address 1001 4th Ave, # 3200 Seattle,
WA 98154, U.S.
Country United States
Categories Health , Marketing , Research
Tags genital warts treatment market , genital warts treatment market analysis , genital warts treatment market outlook
Last Updated February 8, 2022